As the intention ofupcoming clinical trials of Aβ-directed therapeutics is to target patientswith early and prodromal AD [46,47], thereis still a potential for differential responses to treatment among carriersof various APOE alleles. This evidence concerns the gene APOE and Alzheimer disease.